Cartesian Therapeutics
RNAC
72 hedge funds and large institutions have $86.7M invested in Cartesian Therapeutics in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
6% more funds holding
Funds holding: 68 → 72 (+4)
0.5% less ownership
Funds ownership: 25.91% → 25.41% (-0.5%)
27% less capital invested
Capital invested by funds: $119M → $86.7M (-$32.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$1.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.32M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$1.24M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$690K |
| 5 |
State Street
Boston,
Massachusetts
|
+$509K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.49M |
| 3 |
JP Morgan Chase
New York
|
-$1.42M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$790K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$536K |
RNAC Hedge Fund Activity: Q1 2025 in Review
72 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2025, worth a combined $86.7M — down 27% from $119M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RNAC positions and 7 closed out — a net gain of 5 holders — while 22 added to existing stakes and 20 trimmed.
The largest buyer was Erste Asset Management, adding an estimated $1.54M. The largest seller was Citadel Advisors, cutting an estimated $3M.
- 72 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2025, up from 68 in Q4 2024.
- Funds reported $86.7M of Cartesian Therapeutics stock for Q1 2025, down 27% quarter-over-quarter.
- 12 funds opened new Cartesian Therapeutics positions in Q1 2025 and 7 closed out, a net change of +5 holders.
- The largest Cartesian Therapeutics buyer in Q1 2025 was Erste Asset Management, an estimated $1.54M added.
- The largest Cartesian Therapeutics seller in Q1 2025 was Citadel Advisors, an estimated $3M sold.
Based on aggregated 13F filings for Q1 2025.